⌘K

07:05:00·1979d

PRReleasevia Quantisnow

uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.

QURE· uniQure N.V.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

QURE
uniQure N.V.
Health Care

Recent analyst ratings

Mar 11UpdateMizuho$35.00
Mar 9UpdateRBC Capital Mkts$35.00
Mar 9UpdateWells Fargo$60.00
Mar 3UpdateWells Fargo$15.00
Mar 3UpdateMizuho$12.00
Mar 2UpdateRBC Capital Mkts$11.00

Related

SEC2d
uniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
PR2d
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease
PR4d
uniQure to Announce First Quarter 2026 Financial Results
SEC5d
SEC Form DEFA14A filed by uniQure N.V.
SEC5d
SEC Form DEF 14A filed by uniQure N.V.
SEC15d
SEC Form PRE 14A filed by uniQure N.V.
ANALYST52d
uniQure upgraded by Mizuho with a new price target
INSIDER53d
Chief Customer & Strat Officer O'Keefe Kylie was granted 19,800 units of Ordinary Shares, increasing direct ownership by 19% to 124,800 units (SEC Form 4)